

FORM PTO-1390 (Modified) (REV. 11-2000)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER DC-0190	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371				U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR <div style="font-size: 1.5em; font-weight: bold; text-align: center;">10/089475</div>	
INTERNATIONAL APPLICATION NO. PCT/US00/27443		INTERNATIONAL FILING DATE 4 October 2000		PRIORITY DATE CLAIMED 6 October 1999	
TITLE OF INVENTION COMPOSITIONS AND METHODS FOR MODULATING ATP-BINDING CASSETTE TRANSMEMBRANE REPORTER PROTEIN EXPRESSION					
APPLICANT(S) FOR DO/EO/US HAMILTON, Joshua W. and STANTON, Bruce A.					
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: <ol style="list-style-type: none"> 1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3. <input type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (24) indicated below. 4. <input type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (Article 31). 5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371 (c) (2)) <ol style="list-style-type: none"> a. <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> has been communicated by the International Bureau. c. <input checked="" type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). 6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). <ol style="list-style-type: none"> a. <input type="checkbox"/> is attached hereto. b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4). 7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3)) <ol style="list-style-type: none"> a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> have been communicated by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input checked="" type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)). Unexecuted 10. <input type="checkbox"/> An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)). 11. <input type="checkbox"/> A copy of the International Preliminary Examination Report (PCT/IPEA/409). 12. <input checked="" type="checkbox"/> A copy of the International Search Report (PCT/ISA/210). <p>Items 13 to 20 below concern document(s) or information included:</p> <ol style="list-style-type: none"> 13. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 14. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 15. <input type="checkbox"/> A FIRST preliminary amendment. 16. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. 17. <input type="checkbox"/> A substitute specification. 18. <input type="checkbox"/> A change of power of attorney and/or address letter. 19. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825. 20. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4). 21. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4). 22. <input checked="" type="checkbox"/> Certificate of Mailing by Express Mail 23. <input checked="" type="checkbox"/> Other items or information: <ol style="list-style-type: none"> 1) Courtesy copy of the International Application; 2) Return post card. 					

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR 1.101) 10/089475		INTERNATIONAL APPLICATION NO. PCT/US00/27443		ATTORNEY'S DOCKET NUMBER DC-0190	
---	--	--	--	--	--

24. The following fees are submitted: BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :				CALCULATIONS PTO USE ONLY	
<input type="checkbox"/> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$1040.00					
<input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$890.00					
<input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$740.00					
<input checked="" type="checkbox"/> International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$710.00					
<input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00					
ENTER APPROPRIATE BASIC FEE AMOUNT =				\$710.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than _____ <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (e)).				\$0.00	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	11 - 20 =	0	x \$18.00	\$0.00	
Independent claims	1 - 3 =	0	x \$84.00	\$0.00	
Multiple Dependent Claims (check if applicable). <input type="checkbox"/>				\$0.00	
TOTAL OF ABOVE CALCULATIONS =				\$710.00	
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				\$355.00	
SUBTOTAL =				\$355.00	
Processing fee of \$130.00 for furnishing the English translation later than _____ <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (f)).				\$0.00	
TOTAL NATIONAL FEE =				\$355.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable). <input type="checkbox"/>				\$0.00	
TOTAL FEES ENCLOSED =				\$355.00	
				Amount to be: refunded	\$
				charged	\$

a. ☐ A check in the amount of _____ to cover the above fees is enclosed.


b. ☒ Please charge my Deposit Account No. **50-1619** in the amount of **\$355.00** to cover the above fees. A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. **50-1619**. A duplicate copy of this sheet is enclosed.

d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. **Credit card information should not be included on this form.** Provide credit card information and authorization on PTO-2038.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Jane Massey Licata, Registration No. 32,257 Licata & Tyrrell P.C. 66 East Main Street Marlton, N.J. 08053 Tel: 856-810-1515 Fax: 856-810-1454	<div style="text-align: center;">  SIGNATURE </div> <div style="text-align: center;"> Jane Massey Licata NAME </div> <div style="text-align: center;"> 32,257 REGISTRATION NUMBER </div> <div style="text-align: center;"> March 28, 2002 DATE </div>
--	---

100894750128 MAR 2002

10/089475

COMPOSITIONS AND METHODS FOR MODULATING ATP-BINDING
CASSETTE TRANSMEMBRANE REPORTER PROTEIN EXPRESSION

Background of the Invention

A family of proteins found on the surface of cells is known as the ATP-binding cassette (ABC) family of transmembrane reporter proteins. Expression of these proteins affects the transport of drugs into cells. This family of proteins includes the trans-membrane ATP-dependent drug translocation protein P-glycoprotein (Pgp; Nooter, K. and Sonneveld, P. *Leuk. Res.* 1993 18:233-243; Biedler, J.L. *Cancer Res.* 1994 54:666-678; Kerbel et al. *Cold Spring Harbor Symp. Quant. Biol.* 1994 59:661-672; Broxterman et al. *Curr. Opin. Oncol.* 1995 7:532-540; and List, A.F. *Leukemia* 1996 10:937-942); the Multi-drug Resistance-associated Protein (MRP) whose overexpression is associated with multi-drug resistance (Demolombe, S. and Escande, D. *TIPS* 1996 17:273-275); the Cystic fibrosis Transmembrane Conductance Regulator protein (CFTR), mutations of which cause cystic fibrosis (Schneider et al. *British J. Cancer* 1989 60:815-818); and the Sulfonourea Receptor (SUR) protein (Fojo et al. *Proc. Natl. Acad. Sci. USA* 1987 84:265-269). The ability to modulate the expression of these proteins has broad application in a variety of clinical situations including multi-drug resistance in cancer and cystic fibrosis.

Pgp is expressed in a variety of normal tissues including liver, kidney and colon and tumors arising from these tissues usually over-express Pgp as part of their multi-drug resistance (MDR) phenotype (Cole et al. *Science* 1992 258:1650-1654; Roninson, I.B. *Biochem. Pharmacol.* 1992 43:95-102; Arceci, R.J. *Blood* 1993 81:2215-2222; and Merkel et al. *J. Clin. Oncol.* 1989 7:1129-1136). However, Pgp can also be over-expressed in tumors from tissues that do not normally express this protein, such as breast and ovarian tissues

- 2 -

(Arceci, R.J. *Blood* 1993 81:2215-2222; and Ihnat et al. *Clin. Cancer Res.* 1997 3:1339-1346). The mechanism of Pgp up regulation in tumors in vivo is still unclear, but can occur de novo as in acute myelogenous leukemia (AML) (Gregorcyk et al. *Ann. Surg. Oncol.* 1996 3:8-14; Koh et al. *Yonsei Medical Journal* 1992 33:137-142; Dalton, W.S. and Sikic, B.I. *J. NIH Res.* 1994 6:54-58; Cole et al. *Science* 1992 258:1650-1654; Demolombe, S. and Escande, D. *TIPS* 1996 17:273-275; Schneider et al. *British J. Cancer* 1989 60:815-818; Fojo et al. *Proc. Natl. Acad. Sci. USA* 1987 84:265-269; Roninson, I.B. *Biochem. Pharmacol.* 1992 43:95-102; Arceci, R.J. *Blood* 1993 81:2215-2222; and Merkel et al. *J. Clin. Oncol.* 1989 7:1129-1136) or can be acquired over the course of cancer treatment as in breast and ovarian cancer (Merkel et al. *J. Clin. Oncol.* 1989 7:1129-1136; Ihnat et al. *Clin. Cancer Res.* 1997 3:1339-1346; Hamilton, J.W. and Wetterhahn, K.E. *Mol. Carcinogens* 1989 2:274-286; and McCaffrey et al. *Mol. Carcinogens* 1994 10:189-198).

MDR1 gene transcription and *MDR1* mRNA expression can be induced by certain DNA damaging agents, including chemotherapeutic drugs such doxorubicin, simple alkylating agents such as methyl methanesulfonate, and genotoxic chemical carcinogens that induce bulky DNA adducts such as aflatoxin B1 and 2-acetylaminofluorene. In contrast, Pgp mRNA and overall protein expression has been shown to be significantly suppressed by treatment with DNA crosslinking agents, including the cancer chemotherapy drugs, mitomycin C (MMC), cisplatin, carboplatin, and BMS181174, and the carcinogen, chromium(VI). The principal mechanism for the suppression appears to be a down-regulation of *MDR1* gene transcription occurring immediately after drug treatment.

However, in a March 1999 Abstract by Maitra et al., it is suggested that there may be a second point of Pgp regulation that mediates changes in Pgp trafficking from an

- 3 -

intracellular pool to the cell surface in direct response to a toxic chemical challenge. This suggestion is based upon experiments with a gene construct expressing a Pgp-green fluorescent protein fusion protein under the control of the *MDR1* gene promoter in MDCK. MMC treatment was shown to increase membrane levels of Pgp-GFP 6-18 hours after treatment. These levels were reported to subsequently decrease to half the control value by 40 to 60 hours and then return to normal. No details regarding preparation of this construct are disclosed in the Abstract.

Like Pgp, CFTR is a member of the ABC family of transmembrane reporter proteins. Hundreds of different individual CFTR mutations falling into five functional classes have been identified, including missense mutations, frameshifts, in-frame deletions, and splicing mutants. A single mutation resulting in a deletion of the phenylalanine at position 508 of the CFTR protein, known as $\Delta F508$, accounts for approximately 67% of mutations in all CF patients. This mutation results in improper CFTR protein folding and trafficking such that functional CFTR does not reach the cell membrane surface. Experiments in cell culture that are able to overcome the blockade of this mutant CFTR from reaching the cell surface indicate that if $\Delta F508$ reaches the cell membrane it functions normally.

Gene constructs and cells transfected with these constructs have now been produced that have the ability to affect expression of these ABC reporter proteins.

Summary of the Invention

An object of the present invention is a genetic construct which comprises a cDNA for an ABC reporter gene linked to a cDNA for a reporter gene under regulation of a proximal promoter region of the reporter gene. These constructs can comprise the human CFTR coding region and a cDNA of a EGFP reporter gene linked at the 5' end to the human

- 4 -

CFTR cDNA coding region and wherein said cDNAs are under the regulation of the proximal human CFTR promoter region, as well as the human Pgp cDNA coding region linked to a cDNA for a reporter gene under the regulation of the proximal human MDR1 promoter region. Also encompassed by the present invention are cell lines transfected with the genetic constructs.

Another object of the present invention is a method for assessing the ability of antineoplastic agents to induce multi-drug resistance in tumor cells which comprises exposing cells transfected with the constructs of the present invention wherein the construct comprises a human Pgp cDNA coding region linked to a cDNA for a reporter gene under the regulation of a proximal human MDR1 promoter region to an antineoplastic agent; and then monitoring MDR1 gene transcription in the cells and Pgp protein trafficking to the surface of the cells wherein an increase in both MDR1 gene transcription in the cells and Pgp protein trafficking to the surface of the cells is indicative of the agent inducing a multi-drug resistant phenotype in tumor cells.

Yet another object of the present invention is a method for identifying agents which alter the *de novo* multi-drug resistant phenotype of tumor cells which comprises contacting cells transfected with a constructs of the present invention wherein said construct comprises a human Pgp cDNA coding region linked to a cDNA for a reporter gene under the regulation of the proximal human MDR1 promoter region with an agent; and monitoring MDR1 gene transcription in the cells and Pgp protein trafficking to the surface of the cells, wherein a decrease in MDR1 gene transcription in the cells or Pgp protein trafficking to the cell surface is indicative of an agent which is useful in inhibiting the *de novo* multi-drug resistant phenotype of some tumor cells.

Another object of the present invention is a method for identifying agents for use in the treatment of cystic fibrosis

- 5 -

which comprises exposing cells transfected with the genetic construct of the instant invention to an agent; measuring CFTR expression levels or trafficking of CFTR to the cell membrane in the exposed cells; and comparing measured CFTR expression
5 levels or trafficking of CFTR to the cell membrane in the exposed cells to CFTR expression levels or trafficking of CFTR to the cell membrane in cells not exposed to the agent, wherein an increase in CFTR expression levels or trafficking of CFTR to the cell membrane in the exposed cells as compared
10 to the unexposed cells is indicative of the agent being useful in the treatment of cystic fibrosis. This method can be used to identify agents for treating cystic fibrosis in a patient.

Detailed Description of the Invention

Gene constructs of ABC reporter proteins have been
15 produced which express a green fluorescent protein (GFP)-tagged human ABC reporter protein under the transcriptional control of a promoter that is related functionally to the ABC reporter protein. These constructs have been used to stably transfect cell lines for use in elucidating mechanisms of MDR
20 that involves Pgp expression as well as identifying agents that can increase expression of CFTR. In the case of both the Pgp and CFTR proteins, the common link is preparation of the genetic construct using a green fluorescent protein (GFP)-tagged human ABC reporter protein under the transcriptional
25 control of a promoter. These constructs can be used to determine whether agents are capable of modulating expression of the ABC reporter protein being studied. In the context of the present invention, "modulating" can be either increasing or decreasing protein expression.

30 Modulating Expression of CFTR

The first application of an ABC reporter gene construct of the present invention was to increasing expression of CFTR in cystic fibrosis (CF) patients since it has been calculated

- 6 -

that only a small fraction of normal expression of this protein is needed to have clinical benefit in CF patients. Therefore, strategies to increase the expression and/or trafficking of mutants such as $\Delta F508$ CFTR, which has been
5 shown to function normally upon trafficking to the cell surface, are expected to have clinical benefit in CF patients. It is also believed that such a strategy is applicable to all CF mutations in this functional class.

The present invention relates to gene constructs and
10 cells transfected with these constructs which can be used to identify pharmacological agents for use in increasing CFTR protein expression and thus in potentially treating cystic fibrosis. Gene constructs of the present invention comprise a human CFTR cDNA coding region linked at the 5' end to a cDNA
15 for a marker or reporter gene under the regulation of the proximal human CFTR promoter region. In a preferred embodiment, approximately 1200 base pairs of the proximal human CFTR promoter region are included in the construct. The construct is cloned into a standard commercially available
20 genetic backbone such as the PGL3-basic genetic backbone. Either wild-type or a mutant CFTR cDNA is used. In a preferred embodiment, the CFTR cDNA is mutant $\Delta F508$ CFTR cDNA.

The cDNA of the marker gene is preferably jellyfish green fluorescent protein (GFP) and more preferably humanized
25 EGFP or modified, humanized EGFP. GFP fusion proteins have recently emerged as unique tools in cell biology to study such complex phenomena as the distribution and dynamics of intracellular organelles and the trafficking of proteins in intact, living cells (Cubitt et al. Trends Biochem. Sci. 1995
30 20:448-455). GFP, a 27 kDa protein generates a striking green fluorescence without the addition of substrates, cofactors or antibodies (Cubitt et al. Trends Biochem. Sci. 1995 20:448-455; Marshall et al. Neuron 1995 14:211-215; and Prasher et al. Gene 1992 111:229-233). GFP fusion proteins in living
35 cells have been used to study the real-time trafficking of the

- 7 -

glucocorticoid receptor to the nucleus (Htun et al. Proc. Natl Acad. Sci. USA 1996 93:4845-4850; and Ogawa et al. Proc. Natl Acad. Sci. USA 1995 92:11899-11903), and proteins through the secretory pathway (Kaether, C. and Gerdes, H.-H FEBS Lett. 5 1995 369:267-271). The fusion of GFP to ion channels and other proteins generally does not alter the function or localization of these proteins, and GFP is non-toxic (Cubitt et al. Trends Biochem. Sci. 1995 20:448-455; Marshall et al. Neuron 1995 14:211-215). EGFP has been modified to express a 10 "humanized" GFP that is brighter and more stable in mammalian cells than the original GFP. More recently a version of EGFP has been generated with a shorter half-life, since GFP is very stable and may therefore interfere with longer term studies of proteins to which it is attached.

15 The constructs of the present invention are designed to be either transiently or stably expressed in mammalian epithelial cell lines and to preferably express the hybrid GFP-CFTR mutant or wild-type protein which can be followed by GFP fluorescence. For example, stably transfected cell lines 20 have been prepared by transfecting these gene constructs into the MDCK canine kidney parental cell line to generate pure sub-clones stably expressing one or more integrated copies of the CFTR-EGFP-CFTR transgene.

The expressed protein can be followed, for example, via 25 flow cytometry, confocal microscopy or by antibodies to the GFP at the protein level, or by detection of unique mRNA sequences of the EGFP and EGFP-fusion product in mammalian cells via northern blotting, S1 protection or RT-PCR assays.

Cell lines transfected with the gene constructs can be 30 used to better elucidate wild-type and mutant CFTR expression and trafficking. These cell lines can also be used to screen and identify agents which increase functional cell surface protein expression of a mutant CFTR. Agents which increase expression and/or trafficking of CFTR to the cell membrane are 35 expected to increase functional cell surface protein

- 8 -

expression. Accordingly, screening assays can be performed in accordance with well known techniques in cells transfected with a gene construct of the present invention to identify agents which increase levels of CFTR expression by measuring
5 levels of fluorescence in transfected cells exposed to the agent and transfected cells not exposed to the agent. Increased fluorescence levels in transfected cells exposed to the agent as compared to transfected cells not exposed to the agent are indicative of the agent increasing expression of
10 CFTR. Alternatively, agents which increase trafficking of the protein to the cell membrane surface can be identified by measuring levels of cell surface CFTR via measurement of fluorescence at the cell surface or via antibodies specific to EGFP. Increased levels of cell surface CFTR in transfected
15 cells exposed to the agent as compared to transfected cells not exposed to the agent are indicative of the agent increasing trafficking of the CFTR protein to the cell membrane surface. In a preferred embodiment, these screening assays are performed in cells transfected with a gene
20 construct comprising a mutant CFTR cDNA such as the human $\Delta F508$ mutant.

Results from these screening assays can then be confirmed in cell lines derived directly from airway epithelial cells of normal and CF patients.

25 Agents identified to increase expression and/or trafficking of CFTR, and in particular mutant CFTR such as $\Delta F508$, are expected to be useful in treating cystic fibrosis. These agents can thus be incorporated into compositions with pharmaceutically acceptable vehicles and administered
30 systemically to patients with cystic fibrosis, especially patients with cystic fibrosis resulting from a mutant CFTR such as $\Delta F508$, so that the agent can reverse the phenotype of cystic fibrosis caused by the mutant.

Experiments were performed which identified specific
35 agents that increase functional cell surface expression of the

- 9 -

$\Delta F508$ CFTR protein. In these experiments, the effects of mitomycin C (MMC) and the anthracycline drug, doxorubicin (Dox), on wild-type CFTR mRNA expression were examined using the HT-29 human colon cell line. A single non-toxic treatment of the cells with MMC led to a significant increase in CFTR mRNA expression over a 72 hour period. Little or no effect of MMC on CFTR mRNA expression was observed in these cells between 0 and 36 hours after treatment. However, a rapid increase in CFTR mRNA to 1.5-fold over controls was seen by 48 hours and remained high through the end of the experiment.

The effect of MMC and Dox on CFTR protein levels were then examined by western blotting using anti-CFTR antibodies. The correlation between increased levels and increased functional CFTR in the cell membrane was also examined either by measuring chloride permeability using MQAE fluorescence or trans-epithelial chloride currents using the Ussing chamber assay. MMC significantly increased mature CFTR protein levels in T84 cells, and statistically increased chloride currents by approximately 1.2-fold. MMC effects were then compared to those of the anthracycline drug, Dox, in this system. It was found that treatment of the cells with Dox caused an even greater effect on CFTR protein levels and CFTR-associated chloride currents than did MMC. Dox increased total cellular CFTR protein levels by 1.6- to 2-fold in T84 cells, and levels were maximal at approximately 18 to 24 hours after treatment. Dox had an even greater effect on the levels of cell surface CFTR as demonstrated by cell surface biotinylation and immunoprecipitation followed by western blotting. Dox increased the amount of cell surface-detectable CFTR by approximately 2.5- to 3-fold in these cells. Dox treatment of T84 cells was also determined to increase CFTR-associated chloride currents by approximately 2.1-fold as measured by the Ussing chamber assay and to increase chloride permeability by approximately 2-fold as measured by MQAE fluorescence in these cells.

- 10 -

The ability of Dox to increase functional expression of $\Delta F508$ CFTR in a similar manner was then assessed. In initial experiments, the effects of Dox on $\Delta F508$ CFTR expression were examined in a canine kidney MDCK-derived cell line that had
5 been stably transfected with a human $\Delta F508$ CFTR cDNA construct expressed under the control of a CMV promoter. As controls, the effects of Dox on CFTR expression in the wild-type parental MDCK-C7 cells from which the stable cell line was derived and an MDCK-derived cell line stably transfected with
10 GFP-tagged wild-type human CFTR also under the control of the CMV promoter were examined. Dox had no effect on chloride currents in either controls. However, Dox statistically significantly increased chloride currents in the cell line expressing the human $\Delta F508$ CFTR by approximately 1.7-fold.

15 Thus, these experiments demonstrated that treatment of cells with very low concentrations of the anthracycline drug Dox increased expression of functional CFTR and $\Delta F508$ CFTR at the cell surface. While concentrations of the anthracycline drug demonstrated to be effective in these assays were
20 completely non-toxic to cells, the systemic non-target toxicity of agents such as Dox and MMC may limit their utility in treating patients with cystic fibrosis. However, these experiments clearly provide the expectation that less toxic anthracycline drugs and derivatives or metabolites thereof
25 will have similar beneficial properties. Accordingly, anthracycline drugs and derivatives or metabolites thereof are an example of one class of pharmacological agents which can be used in compositions and methods of the present invention to increase functional cell surface protein expression of a
30 mutant CFTR so that the phenotype of cystic fibrosis caused by this mutant is reversed. Examples of pharmacologic agents in this class include, but are not limited to, doxorubicin, idarubicin, anthracenedione derivatives such as mitoxantrone and metabolites such as doxorubicinal.

- 11 -

Modulating Expression of Pgp

Acquired drug resistance is a significant clinical issue in human cancers. In breast cancer, for example, newly diagnosed tumors that have not been pretreated with chemotherapy have little or no expression of Pgp and respond well to a variety of Pgp substrate drugs such as the anthracyclines and the taxanes. In fact, the largest study to date reported no detectable Pgp expression in 248 consecutive samples (Dixon et al. *British J. Cancer* 1992 66:537-541). However, following repeated rounds of chemotherapy with a Pgp substrate agent such as doxorubicin, expression of Pgp was detected in 62% of all specimens examined (Dalton, W.S. and Sikic, B.I. *J. NIH Res.* 1994 6:54-58; Fojo et al. *Proc. Natl. Acad. Sci. USA* 1987 84:265-269; and Miyazaki et al. *Biochem. Biophys. Res. Commun.* 1992 187:677-684). The acquisition of a drug resistance phenotype is one of the primary reasons for the loss of responsiveness in late stage tumors.

The *MDR1* gene coding for Pgp is an inducible gene whose expression can be modulated by drugs, hormones and other stimuli (Chieli et al. *Carcinogenesis* 1994 15:335-341; Thorgeirsson et al. *Pharmac. Ther.* 1991 49:283-292; and Schrenk et al. *Carcinogenesis* 1994 15:2541-2546). For example, the rat *MDR1* gene was demonstrated to be induced by treatment of rat hepatocytes with various DNA damaging agents causing monoadducts, including simple alkylating agents such as methyl methanesulfonate, agents that cause bulky monoadducts such as aflatoxin B1 and 2-acetylaminofluorene, and by anthracyclines and their derivatives, such as doxorubicin and mitoxanthrone (Silverman, J.A. and Hill, B.A. *Mol. Carcinogens* 1995 13:50-59; Schrenk et al. *Biochem. Pharmacol.* 1996 52:1453-1460; and Hamilton et al. *Environ. Hlth. Perspect.* 1998 106:1005-1015). However, treatment with the DNA crosslinking agent mitomycin C (MMC; 0.1 μ M, 4 hours) of cancer cells that naturally overexpress Pgp at levels

- 12 -

comparable to those in MDR cancers *in vivo* was demonstrated to lead to a significant decrease in *MDR1* mRNA and subsequent Pgp protein expression. Pgp protein levels were at their lowest between 48-84 hours after a single MMC treatment before
5 recovering to control levels. This suppression occurred in both rodent and human cell lines, in those derived from tumors of the breast, colon, kidney, liver, brain, and from acute leukemia, and in cells grown either as adherent monolayers or as non-adherent spheroid cultures. The primary target for
10 suppression of Pgp expression by MMC and other DNA crosslinking agents is believed to be transcription of the *MDR1* gene and it has been hypothesized that this is a direct or indirect result of formation of DNA crosslinks by these agents at or near the *MDR1* proximal promoter.

15 However, in subsequent comparisons of membrane versus total cellular Pgp levels, a transient, approximately two-fold increase was observed in membrane-associated Pgp within the first 24 hours after MMC treatment, during a period when total cellular Pgp levels were unchanged. At subsequent time
20 points, there was a parallel decrease in both total and membrane Pgp to levels well below control, and this appeared to be a consequence of the significant decrease in *MDR1* mRNA levels previously observed within the first 24 hours after MMC treatment (Hamilton, J.W. and Wetterhahn, K.E. *Mol.*
25 *Carcinogens* 1989 2:274-286).

These studies are indicative of there being a second target for effects of these chemotherapy agents on Pgp expression. This second step involves the trafficking and/or maturation of nascent Pgp protein. No change in Pgp
30 expression is involved. Instead, there is a change in net movement of existing Pgp protein from an intracellular pool to the cell surface in response to MMC and Dox treatments. Understanding the regulation of this step is important in evaluating the overall MDR response of a tumor to
35 chemotherapy.

- 13 -

In order to more directly assess the effects of drugs on membrane Pgp protein expression, the gene constructs of the present invention were used. Specifically, a construct that expresses a green fluorescent protein (GFP)-tagged human Pgp protein under the control of the human *MDR1* promoter region was produced. This construct was stably transfected into MDCK-C7 canine kidney cells. Single cells expressing GFP-Pgp were isolated by FACS, independent cell lines were established by sub-cloning, and these lines were then characterized for GFP-Pgp expression. Three different cell lines, designated MDR4, MDR10 and MDR29, expressed a protein that was detectable by Western blotting with an anti-Pgp antibody, which migrated at the predicted size of the hybrid protein, and which was not detected in the C7 parental line. Moreover, there was little or no cross-reacting signal at lower molecular weights for either antibody. This indicated that alternative forms and/or breakdown products of the hybrid protein were not present to a significant degree and that the predominant expressed form in these cells was that of full length GFP-Pgp protein. The parental line and the three transfected cell lines also expressed a protein corresponding to the size of native canine Pgp, which is also detectable with C219 but not with human-specific antibodies. The mean GFP fluorescence of cells from the three MDR cell lines correlated closely with their level of expression of GFP-Pgp as shown by Western blotting.

While the reporter gene for this particular construct was green fluorescent protein, as will be obvious to those of skill in the art upon this disclosure, other reporter genes could be used. However, jellyfish green fluorescent protein (GFP) and more preferably humanized EGFP or modified, humanized EGFP is preferred.

Daunorubicin accumulation, as measured by flow cytometry, was used to assess functional Pgp in each cell line. Daunorubicin is a fluorescent Pgp substrate, and cellular accumulation of this drug has been shown to be a

- 14 -

sensitive and accurate measure of functional Pgp in cells. The three MDR cell lines demonstrated significantly less daunorubicin accumulation than did the parental cell line. These results indicate that these cell lines are expressing
5 the GFP-Pgp protein in a functional form on the cell surface, such that their total Pgp levels are greater than the parental cell line. In addition, treatment of the cells with the Pgp inhibitor, verapamil, partially suppressed daunorubicin accumulation in both the parental and MDR cell lines, although
10 drug accumulation in the presence of verapamil was less in the MDR cell lines than the parental line. However, since verapamil does not fully block Pgp function, this is also consistent with the greater functional GFP-Pgp protein on the cell surface of the transfected cells as compared to the
15 parental cell line.

Cytotoxicity assays also confirmed an increase in functional expression of Pgp in the transfected cells. The EC_{50} for cytotoxicity (colony formation) by the Pgp substrate drug, doxorubicin, was approximately 2.5- to 3.5-fold greater
20 in the MDR cell lines than that of the parental cell line, whereas the EC_{50} for cytotoxicity by the non-Pgp substrate drug, cisplatin, was identical in all four cell lines. These results are consistent with the conclusion that these three MDR cell lines express full length hybrid GFP-Pgp that is
25 expressed on the cell surface in a form that is functionally similar the native Pgp protein. Subsequent experiments were performed with the MDR29 cell line, since this was the highest expresser of the GFP-Pgp protein.

MDR29 cells were treated with a single non-cytotoxic
30 dose of MMC, and GFP-Pgp protein expression was measured either in membrane preparations by Western blotting or in intact cells by flow cytometry using an antibody specific for an external epitope of Pgp. MMC caused an initial two-fold increase in membrane GFP-Pgp at 6-12 hours after treatment.
35 Pgp levels subsequently dropped to approximately half that of

- 15 -

controls by 24 hours and remained low through 72 hours after MMC treatment. Thus, the basic response of GFP-Pgp to MMC in these cells was similar to what was observed previously for native Pgp in H4IIE and other cell lines, although the overall time course for this phenomenon was more rapid in the MDR29 cells. Moreover, the close agreement of the Western and flow cytometry data indicate MMC treatment principally alters cell surface Pgp expression. The functional consequence of these treatments was further confirmed by examining daunorubicin accumulation in MDR29 cells following MMC treatment. There was a significant increase in drug accumulation at 48 hours after MMC, and drug accumulation was increased in both control and MMC-treated cells by verapamil treatment. These results are consistent with a MMC-induced decrease in functional cell surface Pgp expression at 48 hours.

In contrast to the effects of MMC on Pgp expression, treatment of MDR29 cells with the anthracycline, doxorubicin (Dox), resulted in a progressive and substantial increase in membrane Pgp levels over a 24-72 hour period after treatment. Cellular GFP levels were increased earlier and to a greater extent than were Pgp membrane levels following Dox treatment, which is consistent with an initial increase in net cellular levels of GFP-Pgp which was followed by an increase in membrane GFP-Pgp. Since Dox has previously been shown to increase *MDR1* gene transcription and *MDR1* mRNA expression as well as overall cellular expression of Pgp protein (Merker et al. *J. Clin. Oncol.* 1989 7:1129-1136), this suggests that Dox is increasing both *MDR1* and *GFP-MDR1* gene expression and GFP-Pgp protein expression in the MDR29 cells, resulting in an overall increase in net GFP-Pgp membrane levels.

In the case of MMC, net movement of Pgp to the cell surface appears to be a futile response, since the dominant effect of this drug is to suppress Pgp mRNA expression leading to an overall decrease in Pgp protein expression at later times after drug treatment. However, Dox increased both Pgp

- 16 -

mRNA expression and net Pgp movement to the membrane, resulting in a substantial up-regulation of Pgp expression in response to this drug. Thus, it appears that it is the combined effects on these two independent pathways which
5 dictates the overall effects of a given drug on Pgp expression in tumor cells.

As demonstrated by these experiments, these constructs and cells expressing these constructs are useful in assessing the ability of antineoplastic agents to induce a multi-drug
10 resistant phenotype in tumor cells. Cells expressing this construct can be exposed to antineoplastic agents and the effects of the antineoplastic agent on both *MDR1* gene transcription in the cells and Pgp protein trafficking to the surface of the cells can be examined. Agents which increase
15 *MDR1* gene transcription and/or Pgp protein trafficking to the surface of the cells are expected to induce a multi-drug resistant phenotype in tumor cells, whereas agents which suppress either of these steps would be expected to decrease the MDR phenotype.

20 The constructs and cells of the present invention are also useful in identifying agents which alter the *de novo* multi-drug resistant phenotype of some tumor cells. Cells expressing the construct can be exposed to agents and alterations in *MDR1* gene transcription and Pgp protein
25 trafficking to the surface are monitored. A decrease in either *MDR1* gene transcription or Pgp protein trafficking in the cells following exposure to the agent is indicative of an agent which may be useful in inhibiting the *de novo* multi-drug resistant phenotype of some tumor types. Various methods
30 for monitoring gene transcription and protein expression are available. For example, expression of the transgene can be following by Northern blotting, RNase protection or RT-PCR assay for the unique mRNA of the fusion protein. The fusion protein can also be monitored by its fluorescence via
35 techniques such as flow cytometry, confocal microscopy of

- 17 -

fluorescent plate reader technology or by antibodies to GFP of Pgp epitopes at the protein level either in cell lysates or in intact cells at the cell surface by fluorescence.

The following nonlimiting examples are provided to further illustrate the present invention.

EXAMPLES

Example 1: Cell culture and treatments

H4IIE rat hepatoma cells were cultured in accordance with procedures described by Hamilton, J.W. and Wetterhahn, K.E. *Mol. Carcinogens* 1989 2:274-286. Other cells used included Madin Darby canine cells (MDCK-C7). Cells were grown in MEM medium (Gibco/BRL, Gaithersburg, MD) supplemented with 10% fetal bovine serum (FBS, Hyclone, Logan, UT), 50 U/ml penicillin (Sigma Chemical, St. Louis, MO), 50 µg/ml streptomycin (Sigma) and 2 mM L-glutamine (Gibco/BRL). The cells were incubated at 37°C with 5% CO₂, provided with fresh media every two days and passaged once a week. Treatments were performed in serum-free media for 4 hours unless otherwise stated. Control cells were treated with solvent alone in serum-free media. Following treatment, completed media was added back to the cells for time points longer than 4 hours.

Example 2: Cloning

The human MDR promoter (hMDRpro, -996 to +44) (Shi et al. *Clinical Immunology and Immunopathology* 1995 76:44-51) was amplified by PCR from the metastatic breast cancer cell line MDA-MB-435 cells (ATCC, Rockville, MD). Oligonucleotide primers 5'-ACGATTAATTTAAAGAAAGTGGAAACA-3' (sense strand; bases -996 to -979 (Ase I restriction site)) and 5'-CTAGCTAGCCCTAAAGGAAACGAACAG-3' (anti-sense strand; bases +44 to +61 (Nhe I restriction site)) were used to amplify a 1080

- 18 -

bp fragment. Primers were designed using Oligo v4.04 Primer Analysis Software (Plymouth, MN) and synthesized by the Dartmouth College Molecular Biology Core facility. PCR reaction mixtures (100 μ L) contained 100 ng of MDA-MB-435
5 genomic DNA, 200 nM of each dNTP, 200 nM of each primer, 1.5 mM $MgCl_2$, and 0.5-1.0 units of Taq polymerase (Perkin Elmer, Foster City, CA). Hot-start PCR was performed using the following cycling parameters: a) 94°C for 1 minute; b) 2 cycles of 1 minute at 94°C, 2 minutes at 55°C, and 2 minutes at 72°C;
10 c) 24 cycles of 1 minute at 94°C, 1 minute at 55°C, and 2 minutes at 72°C; and d) a final extension at 72°C for 10 minutes. Control PCR reactions, which included no Taq polymerase, no DNA template, or no primers, did not yield detectable reaction products. PCR products were
15 electrophoretically separated on a 1% low melting point agarose gel (Life Technologies; Gaithersburg, MD) in Tris-acetate-EDTA buffer (40 mM Tris-acetate, 2 mM EDTA, pH 8.5), gel-purified using the Wizard PCR Preps DNA Purification System (Promega; Madison, WI), and subcloned into the pCR 3.1
20 vector using the Eukaryotic TA Cloning Kit (Invitrogen; San Diego, CA). Automated DNA sequence analysis was performed using the ABI PRISM Dye Terminator Cycle Sequencing Ready Reaction Kit (Perkin Elmer, Boston MA).

The green fluorescent protein expression vector pEGFP-C1
25 (Clontech, Palo Alto, CA) was digested with *AseI* and *NheI* and the cytomegalovirus (CMV) promoter was excised. pCR 3.1/hMDR promoter was also digested with *AseI* and *NheI* and the hMDR promoter was ligated into the pEGFP-C1 vector in place of the CMV promoter to generate hMDRpro/pEGFP-C1.

30 The human multidrug resistance gene 1 cDNA (*hMDR1*) was obtained from the Oregon Health Science Center. Due to a limited number of restriction sites, the cDNA for *hMDR1* was subcloned in two steps. First, the construct hMDRpro/pEGFP-C1 was digested with *BglII*, Klenow treated, then digested with
35 *EcoRI*. *hMDR1* was digested with *BstUI* and *EcoRI* and the

- 19 -

resulting 1100 bp piece of the *hMDR1* cDNA (EcoRI, BstUI) was ligated into the *hMDRpro/pEGFP-C1* vector to generate *hMDRpro/pEGFP-C1/hMDR1-1100bp*. Second, *hMDRpro/pEGFP-C1/hMDR1-1100bp* was digested with EcoRI/SmaI and *MDR1* was digested with EcoRI/PmeI. The 3300 bp fragment of the *hMDR1* cDNA (EcoRI, PmeI) was ligated to the *hMDRpro/pEGFP-C1/hMDR1-1100bp* fragment to yield *hMDRpro/pEGFP-C1/hMDR1*. All ligation sites were sequenced to verify the correct reading frame.

10 Example 3: Stable Transfections

MDCK-C7 cells were plated at 600,000 cells in a T75 flask (Corning Inc., Acton, MA). Twenty-four hours after plating, cells were transfected with MDR-GFP DNA in PFX-2 PerFect lipid (Invitrogen) in Opti-MEM media (Gibco/BRL) without any supplements, according to the manufacturer's protocol, using a lipid:cdna ratio of 3:1. After 8 hours, the DNA lipid mixture was removed and replaced with completed media. Twelve hours post-transfection, 0-3 mg/ml of G418 (Gibco/BRL) was added to the media to select for cells expressing the *hMDRpro/pEGFP/hMDR1* construct. Two weeks post-transfection, GFP-positive cells were sorted into 96 well plates (Falcon, Becton Dickinson, Franklin Lakes, NJ) at a density of one cell/well by a FACStar Plus (Becton Dickinson, San Jose, CA) cell sorter. Cells were clonally expanded and three clones designated MDR4, MDR10, MDR29 were selected due to bright green fluorescence as visualized by a Fluorescent Microscope (Zeiss Axiophot) equipped with a halogen lamp and a FITC filter set. These clones were further characterized in detail.

30 Example 4: Western Blot analysis

Cells were plated in 6 well plates (Falcon) and grown to confluence. Following treatment, at various time-points the

- 20 -

cells were lysed and total protein was isolated and analyzed by immunoblotting in accordance with procedures described by Hamilton, J.W. and Wetterhahn, K.E. *Mol. Carcinogens* 1989 2:274-286. Pgp was detected with either the C219 monoclonal antibody (Centocor, Inc., Malvern, PA) or the F4 monoclonal antibody (Neomarkers, San Diego, CA). The immunoreactive bands were detected by enhanced chemiluminescence (ECL, Amersham Corp.). For GFP detection, the blots were re-probed with an anti-GFP monoclonal antibody (Clontech). Digital densitometry was performed on the bands using a Lacie Silverscanner 111 and NIH image software as described by Hamilton, J.W. and Wetterhahn, K.E. *Mol. Carcinogens* 1989 2:274-286.

Example 5: Daunorubicin Accumulation

In order to assess Pgp function, cellular accumulation of the fluorescent Pgp substrate drug, daunorubicin, was assayed using flow cytometry. Cells were seeded at 70% confluency and treated for 24 hours with 20 μ M verapamil (Sigma) for 1.5 hours to block transport of daunorubicin. After verapamil treatment, all flasks were treated with 1 μ M daunorubicin (Calbiochem, San Diego, CA) for 1 hour. After the 1 hour daunorubicin treatment, the T25 flasks were washed with phosphate-buffered saline (PBS, without Ca^{2+} or Mg^{2+}) and the cells were trypsinized (Trypsin EDTA, Gibco/BRL) and removed from the flask, pelleted by centrifugation, resuspended in PBS (with Ca^{2+} and Mg^{2+}) and immediately analyzed by FACScan (Becton Dickinson). For each sample 10,000 cells were analyzed for GFP (green, excitation 488 nm, emission 507 nm) and daunorubicin (red, 488 nm/575 nm) fluorescence. Data analysis was performed using CellQuest (Becton Dickinson) software,

Example 6: Flow cytometric detection of GFP and Pgp expression

Evaluation of Pgp expression in flow cytometric studies

- 21 -

of the MDCK/MDR29 cell line was determined using a high-affinity Pgp monoclonal antibody that recognizes an external epitope of the protein conjugated with phycoerythrin with an F:P ratio of 1.0 (Becton Dickinson). Antigen-saturating
5 protein concentrations of the primary and isotype-matched, PE-conjugated control antibody (Pharmingen) were incubated for 30 minutes at room temperature with 250,000 cells from each sample per 50 μ l in PBS with 0.1% sodium azide as per manufacturer's recommendations. Cells were washed, pelleted,
10 resuspended in 500 μ l, fixed with 1% paraformaldehyde, and analyzed immediately. Ten thousand events were collected per sample in list-mode files during laser excitation in the FACScan Analyzer using LYSIS II software (Becton Dickinson) for each experiment. Identical detection settings were used
15 for all studies. Data were processed using CellQuest software (Becton Dickinson).

All studies were conducted in triplicate with sham-treated controls corresponding to each time point. Time-course evaluations of Pgp and GFP expression were conducted
20 with noncytotoxic doses of MMC and Dox as defined below. Cells were plated in T25 flasks (Falcon) to insure 30-70% confluence during the time course studies (96 hours). Viability in selected samples throughout the time course studies was determined by addition of 7-amino actinomycin D (VIAPROBE,
25 Pharmingen). Pgp and GFP expression in non-viable cell populations were excluded. Median fluorescence of the primary Pgp antibody was corrected for non-specific antibody fluorescence in both the drug-treated and sham-treated samples. Pgp and GFP fluorescence were normalized relative to
30 pretreatment values.

Example 7: Cytotoxicity Assay

Cells were plated in 96 well plates (Fisher, Medford, MA) at a density of 1000 cells per well. Twenty-four hours after plating, the cells were dosed with 0-10 μ M Dox in serum-

- 22 -

free media as described above. The cells were incubated for three days and assayed using the CellTiter 96 AQueous One Solution Reagent (Promega Corp., Madison, WI) using the manufacturer's instructions. The data were collected and
5 analyzed using the Softmax software. A cytotoxicity assay was also performed with cisplatin (0-30 μ M) as described above.

Example 8: Assessment of agents ability to alter CFTR processing or trafficking to the membrane

Confocal microscopy of living cells is used to determine
10 whether agents alter specific steps of CFTR processing or trafficking to the membrane resulting in transient increased expression. Confocal microscopy enables localization of CFTR at the sub-cellular level and permits time-resolved studies in living cells to examine effects of CFTR post-transcriptional
15 expression. In these experiments, cells are grown on filter inserts prior to treatment with varying concentrations of the agent for varying periods of time. For example, for Dox, concentrations ranging between 0.1 and 10 μ M will be examined over a 24 hour period. Confocal microscopy is performed on
20 individual cells and the images are stored and analyzed as described by Moyer et al. J. Biol. Chem. 1998 273:21759-21768. Cell preparations are mounted on a temperature-controlled, flow-through perfusion chamber which allows rapid exchange of solutions. For experiments using living cells, temperature is
25 maintained using a thermally controlled chamber. Confocal z-series is taken at periodic intervals and reconstructed three-dimensionally. This method is referred to as 4-dimensional imaging and produces a consecutive series of 3-dimensional reconstructions which allow one to track the pattern of
30 fluorescence of GFP-CFTR fusion proteins over time. 3-dimensional image reconstruction is used to determine the relationship between internal structures and the plasma membrane. These images can also be rendered in pseudocolor to reveal differences in the intensity of staining in different

- 23 -

parts of the cell. Localization of GFP-CFTR subunits within subcellular compartments including the ER, Golgi apparatus, sub-plasma membrane compartments, and the plasma membrane is performed via a double-labeling approach. Subcellular compartments are identified in the same cells as GFP-CFTR using an array of organelle-specific antibodies and fluorescent markers. By superimposing red fluorescent images of the ER, Golgi apparatus and submembrane and plasma membrane compartments with images of GFP-CFTR, the subcellular distribution and movement of GFP-CFTR in control and agent-exposed cells can be identified.

- 24 -

What is Claimed is:

1. A genetic construct comprising a cDNA for an ABC reporter gene linked to a cDNA for a reporter gene under regulation of a proximal promoter region of the reporter gene.

5 2. The construct of claim 1 wherein the ABC reporter protein cDNA is human CFTR coding region and a cDNA of a EGFP reporter gene linked at the 5' end to the human CFTR cDNA coding region and wherein said cDNAs are under the regulation of the proximal human CFTR promoter region.

10 3. The construct of claim 1 wherein the ABC reporter protein cDNA is human Pgp cDNA coding region linked to a cDNA for a reporter gene under the regulation of the proximal human MDR1 promoter region.

15 4. The construct of claim 2 wherein the human CFTR cDNA is a mutant CFTR.

5. The construct of claim 4 wherein the mutant CFTR is $\Delta F508$.

6. A cell line transfected with the genetic construct of claim 1.

20 7. A method for assessing the ability of antineoplastic agents to induce multi-drug resistance in tumor cells comprising:

(a) exposing cells transfected with the construct of claim 1 wherein the construct comprises a human Pgp cDNA
25 coding region linked to a cDNA for a reporter gene under the regulation of a proximal human MDR1 promoter region to an antineoplastic agent; and

(b) monitoring MDR1 gene transcription in the cells and Pgp protein trafficking to the surface of the cells wherein an

- 25 -

increase in both *MDR1* gene transcription in the cells and Pgp protein trafficking to the surface of the cells is indicative of the agent inducing a multi-drug resistant phenotype in tumor cells.

5 8. A method for identifying agents which alter the *de novo* multi-drug resistant phenotype of tumor cells comprising:

(a) contacting cells transfected with a construct of claim 1 wherein said construct comprises a human *Pgp* cDNA coding region linked to a cDNA for a reporter gene under the
10 regulation of the proximal human *MDR1* promoter region with an agent;

(b) monitoring *MDR1* gene transcription in the cells and Pgp protein trafficking to the surface of the cells, wherein a decrease in *MDR1* gene transcription in the cells or Pgp
15 protein trafficking to the cell surface is indicative of an agent which is useful in inhibiting the *de novo* multi-drug resistant phenotype of some tumor cells.

9. A method for identifying agents for use in the treatment of cystic fibrosis comprising:

20 (a) exposing cells transfected with the genetic construct of claim 4 to an agent;

(b) measuring CFTR expression levels or trafficking of CFTR to the cell membrane in the exposed cells; and

(c) comparing measured CFTR expression levels or
25 trafficking of CFTR to the cell membrane in the exposed cells to CFTR expression levels or trafficking of CFTR to the cell membrane in cells not exposed to the agent, wherein an increase in CFTR expression levels or trafficking of CFTR to the cell membrane in the exposed cells as compared to the
30 unexposed cells is indicative of the agent being useful in the treatment of cystic fibrosis.

10. A method of treating cystic fibrosis in a patient

- 26 -

comprising systemically administering to a patient with cystic fibrosis an agent identified by the method of claim 9.

11. The method of claim 10 wherein the agent comprises an anthracycline drug, derivative or metabolite.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau




(43) International Publication Date
12 April 2001 (12.04.2001)

PCT

(10) International Publication Number
WO 01/25400 A2

- (51) International Patent Classification?: C12N
- (21) International Application Number: PCT/US00/27443
- (22) International Filing Date: 4 October 2000 (04.10.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/158,000 6 October 1999 (06.10.1999) US
60/194,274 3 April 2000 (03.04.2000) US
- (63) Related by continuation (CON) or continuation-in-part (CIP) to earlier applications:
US 60/158,000 (CIP)
Filed on 6 October 1999 (06.10.1999)
US 60/194,274 (CIP)
Filed on 3 April 2000 (03.04.2000)
- (71) Applicant (for all designated States except US):
TRUSTEES OF DARTMOUTH COLLEGE [US/US];
Technology Transfer Office, 11 Rope Ferry Road, Hanover,
NH 03755-1404 (US).
- (72) Inventors; and
(75) Inventors/Applicants (for US only): **HAMILTON, Joshua, W.** [US/US]; 38 Laramie Road, Etna, NH 03750 (US). **STANTON, Bruce, A.** [US/US]; 26 Low Road, Hanover, NH 03755 (US).
- (74) Agents: **LICATA, Jane, Massey et al.**; Law Offices of Jane Massey Licata, 66 E. Main Street, Marlton, NJ 08053 (US).
- (81) Designated States (national): CA, JP, US.
- (84) Designated States (regional): European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
- Published:
— Without international search report and to be republished upon receipt of that report.
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 01/25400 A2

(54) Title: COMPOSITIONS AND METHODS FOR MODULATING ATP-BINDING CASSETTE TRANSMEMBRANE REPORTER PROTEIN EXPRESSION

(57) Abstract: Methods and compositions for modulating cell surface protein expression are provided. The compositions of the present invention are gene constructs comprising ATP-binding cassette transmembrane reporter proteins.

Docket No.
DC-0190

Declaration and Power of Attorney For Patent Application

English Language Declaration

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

Compositions and Methods for Modulating TP-Binding Cassette Transmembrane Reporter Protein Expression

the specification of which

(check one)

☐ is attached hereto.

☒ was filed on October 4, 2000 as United States Application No. or PCT International Application Number PCT/US00/27443 and was amended on _____

(if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Priority Not Claimed

_____ (Number)	_____ (Country)	_____ (Day/Month/Year Filed)	<input type="checkbox"/>
_____ (Number)	_____ (Country)	_____ (Day/Month/Year Filed)	<input type="checkbox"/>
_____ (Number)	_____ (Country)	_____ (Day/Month/Year Filed)	<input type="checkbox"/>

I hereby claim the benefit under 35 U.S.C. Section 119(e) of any United States provisional application(s) listed below:

60/158,000	October 6, 1999
_____ (Application Serial No.)	_____ (Filing Date)
_____ (Application Serial No.)	_____ (Filing Date)
_____ (Application Serial No.)	_____ (Filing Date)

I hereby claim the benefit under 35 U. S. C. Section 120 of any United States application(s), or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. Section 112, I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, C. F. R., Section 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application:

_____ (Application Serial No.)	_____ (Filing Date)	_____ (Status) (patented, pending, abandoned)
_____ (Application Serial No.)	_____ (Filing Date)	_____ (Status) (patented, pending, abandoned)
_____ (Application Serial No.)	_____ (Filing Date)	_____ (Status) (patented, pending, abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. *(list name and registration number)*

Jane Massey Licata, Reg. No. 32,257
 Kathleen A. Tyrrell, Reg. No. 38,350
 Laura M. Plunkett, Reg. No. 45,015
 Bridget C. Sciamanna, Reg. No. 47,333

of the firm

Licata & Tyrrell P.C.
66 E. Main Street
Marlton, New Jersey 08053

Send Correspondence to:



26259

PATENT TRADEMARK OFFICE

Direct Telephone Calls to: *(name and telephone number)*

Jane Massey Licata or Kathleen A. Tyrrell - (856) 810-1515

Full name of sole or first inventor	Joshua W. Hamilton	
Sole or first inventor's signature		Date 7/9/02
Residence	Etna, New Hampshire	
Citizenship	US	
Post Office Address	38 Laramie Road	
Etna, New Hampshire 03750		

Full name of second inventor, if any	Bruce A. Stanton	
Second inventor's signature		Date 8/1/02
Residence	Hanover, New Hampshire	
Citizenship	US	
Post Office Address	26 Low Road	
Hanover, New Hampshire 03755		